Class 435/216 - Streptokinase

Subclass of Class 435 - Chemistry: molecular biology and microbiology
Definition: Subject matter wherein the source of the enzyme which catalyzes
No. of patents: 78
Last issue date: 01/10/2012

«First «Previous1 2 Next»Last»

Number	Title	Issue Date
8093032	Mutants of streptokinase and their covalently modified forms The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their co...	01/10/2012
7465572	De-immunized streptokinase A target protein is rendered less immunogenic to a given species by (a) determining at least part of the amino acid sequence of the target protein; (b) identifying in the amino acid sequence one or more potential epitopes for T-cells (“T-cell epitopes”) of the g...	12/16/2008
7371723	Therapeutic agents comprising pro-apoptotic proteins The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-induc...	05/13/2008
7316910	Rapid test for hemolytic streptococcus A reagent for the detection of an extracellular enzymatically active protein produced by a beta-hemolytic streptococcus bacteria found in a host biological fluid includes a proteinaceous substrate or a cholesterol-containing membrane substrate for the extracellular ...	01/08/2008
7294499	Subtilases The present invention relates to methods for producing variants of a parent TY145 subtilase and of a parent BPN′ subtilase and to TY145 and BPN′ variants having altered properties as compared to the parent TY145/BPN′ subtilase. ...	11/13/2007
7285635	Modified proteins, designer toxins, and methods of making thereof The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositio...	10/23/2007
7250503	Nucleic acid molecules encoding clot-specific streptokinase fusion proteins possessing altered plasminogen activation characteristics The present invention provides polynucleotides encoding clot-specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of na...	07/31/2007
7189557	Process for the intracellular over-production of streptokinase using genetically engineered strain of An improved process for the production of streptokinase using a genetically engineered strain of Escherichia coli which overproduces streptokinase intracellularly and more particularly, the overall process disclosed herein, concerns with an improvement in the...	03/13/2007
7163817	Clot-specific streptokinase proteins possessing altered plasminogen activation characteristics and a process for their preparation The invention disclosed herein provides clot specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokin...	01/16/2007
7115562	Peptides and their use to ameliorate cell death The present invention relates to a method of reducing cell death in a warm-blood animal wherein said cell death associated with a neurodegenerative disorder, an immune disease, a neoplastic disorder, an inflammatory disorder, or a viral disease. The method comprises...	10/03/2006
6899877	Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina A process for inhibiting vascular proliferation separately introduces components into the eye to generate plasmin in the eye in amounts to induce complete posterior vitreous detachment where the vitreoretinal interface is devoid of cortical vitreous remnants. The pr...	05/31/2005
6846656	Process for producing N-acetylneuraminic acid The present invention provides a process for economically producing N-acetylneuraminic acid without using expensive materials such as pyruvic acid and phosphoenolpyruvic acid. The process comprises: allowing (i) a culture of a microorganism having N-acetylneuraminic...	01/25/2005
6638503	STREPTOMYCES MEGASPORUS SD5, PROCESS FOR THE ISOLATION THEREOF, NOVEL FIBRINOLYTIC ENZYME PREPARED THEREFROM, PROCESS FOR THE PRODUCTION OF SAID ENZYME AND METHOD OF TREATMENT OF THROMBOLYTIC DISORDERS USING SAID ENZYME The present invention relates to a novel microorganism Streptomyces megasporus SD5. The present invention also relates to a process for the isolation of said Streptomyces megasporus SD5. The invention also relates to a novel fibrinolytic enzyme actinokina...	10/28/2003
6585972	Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina A process for inhibiting vascular proliferation introduces a composition into the eye inducing posterior vitreous detachment. The composition includes a combination of plasminogen, a collagen crosslinking agent and at least one plasminogen activator selec...	07/01/2003
6488927	Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers....	12/03/2002
6413759	Streptokinase mutants The present invention is related to the field of biotechnology and genetic engineering techniques, particularly to a method for obtaining mutants obtain from streptokinase, to the molecules obtained from this method, as well as the expression vectors and ...	07/02/2002
6403556	Pharmaceutical preparation containing protein C and a thrombolytically active substance A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy....	06/11/2002
6355255	Streptococcal C5a peptidase vaccine Novel vaccines for use against ଲ-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of strepococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mam...	03/12/2002
6309873	Streptokinase mutants The present invention is related to the field of biotechnology and genetic engineering techniques, particularly to a method for obtaining mutants obtain from streptokinase, to the molecules obtained from this method, as well as the expression vectors and ...	10/30/2001
6284475	Assays for diagnosis of thrombophilic disease The present invention provides methods for diagnosing and/or monitoring thrombophilic disease in a patient that can result from the antiphospholipid antibody syndrome (aPL syndrome). The methods of the invention are premised on the inhibition of binding o...	09/04/2001
6239106	Family of protease inhibitors, and other biologic active substances The invention relates to novel protease-inhibitors which are obtainable from leeches. It also relates to uses thereof, for instance as a medicament, thus pharmaceutical preparations are provided, as are derivatives, mutants, genes encoding, vectors compri...	05/29/2001
6210667	Bacterial fibrin-dependent plasminogen activator A pharmaceutical composition in a preferred embodiment comprises an isolated bacterial protein that induces fibrin-dependent plasminogen activation, and methods for dissolving blood clots in a subject use such a composition. Embodiments also include a nuc...	04/03/2001
6190659	Bacterial plasmin binding protein and methods of use thereof The present invention describes a novel polypeptide, and methods of its use in effective thrombolytic therapy in the treatment of coronary and pulmonary thrombosis. Its use is also disclosed in vaccines to abrogate a streptococcal infection. Pharmaceutica...	02/20/2001
6087332	Streptokinase derivatives with high affinity for activated platelets and methods of their production and use in thrombolytic therapy Streptokinase derivatives having platelet glycoprotein binding domains adjacent to the termini of the streptokinase sequence. These derivatives produce higher local concentrations of plasmin in vivo as compared to unmodified streptokinase. Certain of the ...	07/11/2000
5976532	Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or fragments thereof, including c7E3 Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred immunoglobulins are specific for glycoprotein IIb/IIIa re...	11/02/1999
5908625	Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases The invention relates to the use of thromboembolic proteins. These contain, as their only structural portion effecting thrombolytic activity, the protease domain of human tissue type plasminogen activator. These derivatives show reduced side effects, such...	06/01/1999
5876999	Preparation of novel streptokinase mutants as improved thrombolytic agents Mutants of streptokinase in which one or more amino acid residues in the region of Pro58-Lys59-Ser60-Lys61 were replaced by other amino acids become better fibrinolytic agents. The mutants are resistant to the hydrolytic inactivation by plasmin and are mo...	03/02/1999
5858758	Human serine protease precursor The present invention provides a human serine protease precursor (HSPP) and polynucleotides which encode HSPP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provid...	01/12/1999
5854049	Plasmin-resistant streptokinase The invention features modified streptokinase (SK) molecules which are resistant to plasmin cleavage including a recombinant fusion protein in which the amino terminus of SK was blocked with a peptide, a recombinant fusion protein in which an amino-termin...	12/29/1998
5840315	Vaccines based on streptokinase The present invention provides a vaccine to treat or prevent mastitis in a bovine species, comprising an immunologically effective amount of a plasminogen-activating streptokinase protein produced by Streptococcus uberis. The present invention further pro...	11/24/1998
5830467	Pharmaceutical preparation containing protein C and a thrombolytically active substance A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy....	11/03/1998
5736512	Serine protease variants having peptide ligase activity The invention relates to serine protease variants derived from precursor serine proteases via recombinant and/or chemical methods to form protease variants having improved peptide ligase activity. The invention also includes novel ligation substrates whic...	04/07/1998
5731186	Method for the production of rDSPA 댑 rDSPA 댑 is produced in commercial quantities and a purity adequate for clinical standards. The production methods utilize a series of chromatographic steps: cation exchange chromatography, followed by hydrophobic interaction chromatography, and end...	03/24/1998
5723122	Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases The invention relates to the use of thromboembolic proteins. These contain, as their only structural portion effecting thrombolytic activity, the protease domain of human tissue type plasminogen activator. These derivatives show reduced side effects, such...	03/03/1998
5653979	Immunotargeting of plasminogen activators to the pulmonary endothelium A multimolecular complex made up of a plasminogen activator conjugated to anti-ACE Mab 9B9 capable of delivering the plasminogen activator to the pulmonary endothelium is provided. Methods of using this complex to selectively deliver the plasminogen activ...	08/05/1997
5637299	Enhancement of thrombolytic therapy with deglycosylated forms of plasminogen This invention provides an improved method for enhancing the activity of thrombolytic agents, including t-PA, scu-PA, tcu-PA, streptokinase, acylated plasminogen-streptokinase activator complex (APSAC), mixtures of these, and other activators of plasminog...	06/10/1997
5593876	Nitrosylation of protein SH groups and amino acid residues as a therapeutic modality Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to nove...	01/14/1997
5514572	Method to maintain the activity in polyethylene glycol-modified proteolytic enzymes A method for preparing protease-polyethylene glycol adducts is presented wherein the immobilized reversible inhibitor, benzamidine, prevents reaction of activated polyethylene glycol with the active site of the protease. Improved activity against macromol...	05/07/1996
5510330	Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. The invention involves thromboembolically effective compositions and therapeutic methods. Thrombolytically active proteins are combined with anticoagulants, as long as the anticoagulant is not heparin. The anticoagulant is administered in an intravenous b...	04/23/1996
5500411	Method for treating thromboembolic conditions by inhibiting reocclusion via the use of multiple bolus administration of thrombolytically active proteins Discussed are therapeutic approaches to the treatment of thrombolic conditions. The therapies use thrombolytically active proteins which inhibit reocclusion in the subject. The proteins are administered in two or more boli....	03/19/1996

«First «Previous1 2 Next»Last»

PatentStorm

Quotables

PatentStorm News

Class 435/216 - Streptokinase